Now well established across the U.S. and Canada, J&J’s biotech incubator system has expanded into Asia with its first center in China.
PayPal founder Peter Thiel and VC OrbiMed’s Israel unit have helped ChemomAb raise $10 million in a series B round.
When payers and biopharma fight over pricing, patients with rare diseases can suffer. See how Real World Evidence and value-based contracts can help.
The fund will reportedly embark on the spending spree while shifting a “significant” chunk of its operations from the U.S. to the U.K.
The round positions Semma to start learning whether its insulin-producing cells can control blood sugar levels in Type 1 diabetics.
Boston biotech resTORbio raised $40 million aimed at taking its lead candidate for respiratory tract infections in elderly patients into phase 3.
The series C, which moves Codiak’s total haul up toward $170 million, tees the biotech up to move its lead candidate into clinical trials.
The series A positions the startup, Mavupharma, to further its work on the use of oral STING modulators to treat cancer and infectious diseases.
AstraZeneca doubles down on Chinese business through a new drug development joint venture with a state-backed private equity firm.
The $17 million financing equips the lean French biotech to prepare its CTPS1 inhibitors for clinical testing in autoimmune disorders.
The series B equips X4 to move deeper into the clinic on two fronts, with phase 2 and 3 trials in cancers and rare diseases on the horizon.